Adamas Pharmaceuticals, Inc. (ADMS) Stake Lowered by State of Wisconsin Investment Board
State of Wisconsin Investment Board lessened its stake in Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) by 90.1% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 11,000 shares of the specialty pharmaceutical company’s stock after selling 100,000 shares during the quarter. State of Wisconsin Investment Board’s holdings in Adamas Pharmaceuticals were worth $233,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ADMS. Vanguard Group Inc. boosted its holdings in shares of Adamas Pharmaceuticals by 10.3% in the 1st quarter. Vanguard Group Inc. now owns 716,419 shares of the specialty pharmaceutical company’s stock valued at $12,537,000 after buying an additional 66,825 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in Adamas Pharmaceuticals by 212.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 60,897 shares of the specialty pharmaceutical company’s stock valued at $1,066,000 after acquiring an additional 41,436 shares during the period. Fisher Asset Management LLC bought a new stake in Adamas Pharmaceuticals in the 3rd quarter valued at $773,000. Citadel Advisors LLC bought a new stake in Adamas Pharmaceuticals in the 2nd quarter valued at $606,000. Finally, Bamco Inc. NY raised its stake in Adamas Pharmaceuticals by 45.5% in the 2nd quarter. Bamco Inc. NY now owns 103,200 shares of the specialty pharmaceutical company’s stock valued at $1,805,000 after acquiring an additional 32,272 shares during the period. 76.24% of the stock is owned by institutional investors.
Shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) opened at $33.59 on Friday. Adamas Pharmaceuticals, Inc. has a 12 month low of $13.50 and a 12 month high of $34.13. The company has a debt-to-equity ratio of 0.41, a current ratio of 8.35 and a quick ratio of 8.32.
Adamas Pharmaceuticals (NASDAQ:ADMS) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($0.03). The business’s revenue was down 99.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.66) earnings per share. sell-side analysts predict that Adamas Pharmaceuticals, Inc. will post -3.87 EPS for the current year.
A number of equities research analysts recently weighed in on the company. ValuEngine upgraded Adamas Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. Piper Jaffray Companies restated an “overweight” rating and issued a $30.00 price target on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 20th. Zacks Investment Research cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, August 11th. BidaskClub cut Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Finally, Mizuho restated a “buy” rating and issued a $48.00 price target (up previously from $26.00) on shares of Adamas Pharmaceuticals in a research note on Wednesday, September 13th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $42.00.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc is a pharmaceutical company. The Company is engaged in developing medicines to manage the daily lives of those affected by chronic neurologic disorders. It offers a platform based on an understanding of time dependent biologic effects of disease activity and drug response to achieve relief without tolerability issues.
Want to see what other hedge funds are holding ADMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS).
Receive News & Ratings for Adamas Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.